Earnings ·
Reports Q3 revenue of $206.7M and narrows full-year outlook to $850M-$860M
INSPInspire Medical Systems, Inc.
Inspire Medical Systems reported third-quarter revenue of $206.7 million, a 7.9% decline from the prior year period, driven by coding and reimbursement challenges in the U.S. The company posted an adjusted diluted EPS of $0.14 against a GAAP loss per share of $(0.84). Operating cash flow was $46.4 million. Management narrowed its full-year 2026 revenue guidance to $850 million–$860 million and raised the adjusted operating margin outlook to 4.5%–5.5%. The AMA CPT Editorial Panel approved a new Category I code for single-lead hypoglossal nerve stimulation, set to take effect in January 2028. Inspire Medical Systems is a medical technology company focused on developing and commercializing minimally invasive neurostimulation solutions for obstructive sleep apnea.